Impact of angiotensin II on skeletal muscle metabolism and function in mice: Contribution of IGF-1, Sirtuin-1 and PGC-1α

Acta Histochemica

Volumn 115, Issue 4, 2013, Pages 363-370

  Kackstein, Katharina ^a   Teren, Andrej ^a   Matsumoto, Yasuharu ^b   Mangner, Norman ^a   Möbius Winkler, Sven ^a   Linke, Axel ^a   Schuler, Gerhard ^a   Punkt, Karla ^a   Adams, Volker ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Mice; Muscle atrophy; Renin angiotensin aldosterone system; Skeletal muscle; Soleus muscle

Indexed keywords

ACTIN; ALPHA SARCOMERIC ACTIN; ANGIOTENSIN II; ATROGIN 1; MUSCLE RING FINGER 1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN 1; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATROGIN 1 GENE; CONTROLLED STUDY; CYTOPHOTOMETRY; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GLYCOLYSIS; MITOCHONDRIAL RESPIRATION; MOUSE; MUSCLE CONTRACTION; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE RING FINGER 1 GENE; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIRTUIN 1 GENE; SOLEUS MUSCLE; SOMATOMEDIN C GENE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; ORGAN SIZE; RNA, MESSENGER; RNA-BINDING PROTEINS; SIRTUIN 1; TRANSCRIPTION FACTORS;

ANIMALIA; MUS;

EID: 84876303816     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2012.09.009     Document Type: Article

References (37)

1. Benton C.R., Nickerson J.G., Lally J., Han X.X., Holloway G.P., Glatz J.F., et al. Modest PGC-1α overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria. J Biol Chem 2008, 283:4228-4240.
2. Bentzinger C.F., Romanino K., Cloëtta D., Lin S., Mascarenhas J.B., Oliveri F., et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 2008, 8:411-424.
3. Brink M., Price S.R., Chrast J., Bailey J.L., Anwar A., Mitch W.E., et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001, 142:1489-1496.
4. Bücher T., Luh W., Pette D. Einfache und zusammengesetzte optische Tests mit Pyridinnucleotiden. Hoppe-Seyler Thierfelder Handbuch der Physiologisch-und Pathologisch-Chemischen Analyse 1964, 293-339. Springer Verlag, Berlin. K. Lang, E. Lelnartz (Eds.).
5. Buck M., Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 1996, 15:1753-1765.
6. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
7. Francis G.S., Rector R.S., Cohn J.N. Sequential neurohumoral measurements in patients with congestive heart failure. Am Heart J 1988, 116:1464-1468.
8. Garnier A., Zoll J., Fortin D., N'Guessan B., Lefebvre F., Geny B., et al. Control by circulating factors of mitochondrial function and transcription cascade in heart failure: a role for endothelin-1 and angiotensin II. Circ Heart Fail 2009, 2:342-350.
9. Gielen S., Adams V., Möbius-Winkler S., Linke A., Erbs S., Yu J., et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with Chronic Heart Failure. J Am Coll Cardiol 2003, 42:861-868.
10. Hanna I.R., Taniyama Y., Szocs K., Rocic P., Griendling K.K. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 2002, 4:899-914.
11. Inagami T. Molecular biology and signaling of angiotensin receptors: an overview. J Am Soc Nephrol 1999, 10(Suppl. 11):2-7.
12. Keith M., Geranmayegan A., Sole M.J., Kurian R., Robinson A., Omran A.S., et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998, 31:1352-1356.
13. Li Y.P., Chen Y., Li A.S., Reid M.B. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003, 285:C806-C812.
14. Lin J., Wu H., Tarr P.T., Zhang C.Y., Wu Z., Boss O., et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
15. Mangner N., Adams V., Sandri M., Hoellriegel R., Hambrecht R., Schuler G., et al. Muscle function and running activity in mouse models of hereditary muscle dystrophy: impact of double knockout for dystrophin and the transcription factor MyoD. Muscle Nerve 2012, 45:544-551.
16. Middlekauff H.R. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 2010, 3:537-546.
17. Mitsuishi M., Miyashita K., Muraki A., Itoh H. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes 2009, 58:710-717.
18. Montgomery H.E., Marshall R., Hemingway H., Myerson S., Clarkson P., Dollery C., et al. Human gene for physical performance. Nature 1998, 393:221-222.
19. Onder G., Penninx B.W., Balkrishnan R., Fried L.P., Chaves P.H., Williamson J., et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002, 359:926-930.
20. 2+ transients in isolated bundles of skeletal muscle fibers from rats with chronic heart failure. Circ Res 1993, 73:405-412.
21. Philippou A., Maridaki M., Halapas A., Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 2007, 21:45-54.
22. Philp A., Chen A., Lan D., Meyer G.A., Murphy A.N., Knapp A.E., et al. Sirtuin 1 (SIRT1) deacetylase activity is not required for mitochondrial biogenesis or peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a) deacetylation following endurance exercise. J Biol Chem 2011, 286:30561-30570.
23. Punkt K. Fibre types in skeletal muscles. Adv Anat Embryol Cell Biol 2002, 162:1-109.
24. Rezek B.M., Yoshida T., Semprun-Prieto L., Higashi Y., Sukhanov S., Delafontaine P. Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS One 2012, 7:e30276.
25. Rodgers J.T., Lerin C., Gerhart-Hines Z., Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathway. FEBS Lett 2008, 582:46-53.
26. Song Y.H., Li Y., Du J., Mitch W.E., Rosenthal N., Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005, 115:451-458.
27. Sukhanov S., Semprun-Prieto L., Yoshida T., Michael Tabony A., Higashi Y., Galvez S., et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci 2011, 342:143-147.
28. Tabony A.M., Yoshida T., Galvez S., Higashi Y., Sukhanov S., Chandrasekar B., et al. Angiotensin II upregulates protein phosphatase 2Ca and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension 2011, 58:643-649.
29. Tisdale M.J. Biochemical mechanisms of cellular catabolism. Curr Opin Clin Nutr Metab Care 2002, 401-405.
30. Toth M.J., Ades P.A., Tischler M.D., Tracy R.P., LeWinter M.M. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol 2006, 109:179-187.
31. Toth M.J., Matthews D.E., Ades P.A., Tischler M.D., Van Buren P., Previs M., et al. Skeletal muscle myofibrillar protein metabolism in heart failure: relationship to immune activation and functional capacity. Am J Physiol Endocrinol Metab 2005, 288:E685-E692.
32. Vinciguerra M., Fulco M., Ladurner A., Sartorelli V., Rosenthal N. SirT1 in muscle physiology and disease: lessons from mouse models. Dis Model Mech 2010, 3:298-303.
33. Williams A.G., Rayson M.P., Jubb M., World M., Woods D.R., Hayward M., et al. Physiology: the ACE gene and muscle performance. Nature 2000, 403:614.
34. Wu Z., Puigserver P., Andersson U., Zhang C., Adelmant G., Mootha V., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
35. Yoshida T., Semprun-Prieto L., Sukhanov S., Delafontaine P. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol 2010, 298:H1565-H1570.
36. Yu J., Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci 2009, 1173:E10-E19.
37. Zhao W., Swanson S.A., Ye J., Li X., Shelton J.M., Zhang W., et al. Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. Hypertension 2006, 48:637-643.